Please assess the completion status of the following clinical trial:

Trial Title: Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Metastatic breast cancer confirmed by biopsy~* Prior adjuvant/neoadjuvant treatment allowed~* Measurable disease~* Able to perform activities of daily living with minimal assistance~* Age 18 years or older~* Adequate bone marrow, liver and kidney function~* Normal heart function~* Written informed consent~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Pre-existing moderate peripheral neuropathy~* History of significant heart disease~* Meningeal metastases.~* Prior chemotherapy for metastatic breast cancer~* No measurable disease (including bone only, pleural effusions, etc.)~* Receiving Herceptin therapy.~* Women who are pregnant or lactating.~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liposomal Doxorubicin (Type: EXPERIMENTAL): Liposomal doxorubicin 40 mg/m2 by 1 hour IV infusion repeated every 28 days.
- Docetaxel (Type: EXPERIMENTAL): Weekly docetaxel 36 mg/m2 by 30 minute IV infusion on days 1, 8, and 15 of the 28 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).